CD274 and triple-negative breast carcinoma: In in vitro studies, trastuzumab and pertuzumab increased the cytotoxic level of IL-2 activated NK cells targeting ERBB2 positive cancer cell lines [105], and an anti-programmed cell death-ligand 1 (PD-L1) antibody avelumab increased ADCC by NK cells targeting triple negative breast cancer cells [106].